LOIs for research related to RYR-1-RD
The RYR-1 Foundation, a Pittsburgh-based global rare disease organization, assists families and those affected by RYR-1-RD, works with leading researchers around the world, and supports the medical community.
RYR-1-RD are inherited forms of muscle disease that result in a wide range of symptoms, including muscle weakness, a potentially fatal reaction to general anesthesia (malignant hyperthermia), and severe muscle breakdown (rhabdomyolysis), among others. Individuals are born with RYR-1-RD, related to mutations in the RyR1 gene, and mutations in the RyR1 gene are the most common cause of congenital muscle disease.
The foundation invites applications for research from individual investigators. Grants of up to $120,000 over two years will be awarded, with priority given to research that has direct application to clinical therapies for RYR-1-RD. Specific areas of research interest may include the following: novel therapeutic approaches to RYR-1-RD, cell and molecular mechanisms of RYR-1-RD and other muscle disease, and regenerative medicine (RM).
To be eligible, applicants must hold a PhD, MD, DVM, DO, or equivalent degree and have a faculty position/equivalent at a domestic/foreign nonprofit organization, or public/private institution (such as a university, college, medical school, hospital, research institute, or laboratory).
Letters of intent are due May 18, 2024, and upon review, selected applicants will be invited to submit a full proposal, due October 19, 2024.
For complete program guidelines and application instructions, see the RYR-1 Foundation website.
Submissions to this sponsor/donor are managed by the Office of Corporate and Foundation Relations. Please contact your unit-assigned ASUF Director of Development or Research Advancement Specialist at your earliest convenience to ensure ASU's strategic coordination and management of funding applications.